Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Sexual Health · Provider Directory · Updated 2026-06-19

Sexual Health Peptides & Therapies

Sexual health peptides target melanocortin (PT-141 / bremelanotide) and oxytocin pathways for desire and arousal disorders, and GnRH-receptor agonism (gonadorelin, kisspeptin) for endogenous hormone modulation. PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women; the rest are off-label or compounded.

5 peptides covered v3.0 rubric Updated 2026-06-19 All 50 states + DC
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

Peptides in this category

Sexual Health
PT-141
Bremelanotide, Vyleesi
 Sexual Health
Oxytocin
Bonding, arousal
 Sexual Health
Kisspeptin
KISS1, hypothalamic
 Sexual Health
Gonadorelin
GnRH, Factrel
 Sexual Health
Melanotan II
MT-II, melanocortin

Top telehealth providers for sexual health

See the full provider directory for complete profiles, pricing, and v3.0 transparency scoring.

Editorial team

Reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →

Related categories

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing